|
【结 构 式】 
|
【药物名称】EGIS-7625 【化学名称】5-(4-Benzylpiperazin-1-yl)-2-methyl-4-nitroaniline dihydrochloride 【CA登记号】199671-60-8 (monoHCl) 【 分 子 式 】C18H24Cl2N4O2 【 分 子 量 】399.32358 |
【开发单位】Egis (Originator) 【药理作用】PHARMACOLOGICAL TOOLS, 5-HT2B Antagonists |
合成路线1
The title compound was prepared by condensation between 1-benzylpiperazine (I) and 5-chloro-2-methyl-4-nitroaniline (II) in the presence of K2CO3 in either refluxing ethanol or, with a higher yield, in DMF at 120 C. Treatment with HCl in isopropanol furnished the corresponding dihydrochloride salt.
| 【1】 Rátzné Simonek, I.; Bózsing, D.; Jakóczi, I.; Koványiné Lax, G.; Blaskó, G.; Simig, G.; Gacsályi, I.; Schmidt, E.; Miklósné Kovács, A.; Szirtné Kiszelly, E.; Szénási, G.; Gyertyán, I.; Egyed, A.; Tihanyi, K. (Egis Pharmaceuticals Ltd.); Novel piperazine or homopiperazine derivs., pharmaceutical compsns. containing the same and a process for their preparation. WO 9744334 . |
Extended Information